| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/03/2003 | WO2002009761A3 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 01/03/2003 | WO2002009715A3 Use of an arylaldehyde 5-oxo-1, 2, 4-triazine hydrazide for the treatment of cancer |
| 01/03/2003 | WO2002008187A9 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/03/2003 | WO2002005842A3 Preventing airway mucus production by administration of egf-r antagonists |
| 01/03/2003 | WO2002005791A3 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor |
| 01/03/2003 | WO2002002757A3 Adenylyl and guanylyl cyclases |
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2002002563A3 Substituted-triazolopyrimidines as anticancer agents |
| 01/03/2003 | WO2002000727A3 Gp286 nucleic acids and polypeptides |
| 01/03/2003 | WO2002000724A3 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 01/03/2003 | WO2001098357A3 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 01/03/2003 | WO2001098331A3 Glucagon-like peptide-1 analogs |
| 01/03/2003 | WO2001089502A3 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| 01/03/2003 | WO2001081408A9 G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same |
| 01/03/2003 | CA2459985A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2455300A1 Nitrogen-containing heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
| 01/03/2003 | CA2455292A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2455288A1 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/03/2003 | CA2451841A1 Method for enhancing the effectiveness of cancer therapies |
| 01/03/2003 | CA2451686A1 A novel g protein-coupled receptor, gave 3 |
| 01/03/2003 | CA2451664A1 Use of bicyclo compounds for treating alzheimer's disease |
| 01/03/2003 | CA2451625A1 Substituted n-acyl-aniline derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| 01/03/2003 | CA2451271A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2451266A1 Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
| 01/03/2003 | CA2451250A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | CA2451249A1 Amino nicotinate derivatives as glucokinase (glk) modulators |
| 01/03/2003 | CA2451248A1 Composition comprising glycosaminoglycans and hyaluronidase inhibitors for the treatment of arthritic joints |
| 01/03/2003 | CA2451152A1 Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450954A1 Method of treating atherosclerosis and other inflammatory diseases |
| 01/03/2003 | CA2450942A1 Method of treating hyperproliferative diseases using active vitamin d analogues |
| 01/03/2003 | CA2450925A1 G-protein coupled receptors |
| 01/03/2003 | CA2450921A1 Protein modification and maintenance molecules |
| 01/03/2003 | CA2450783A1 Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same |
| 01/03/2003 | CA2450762A1 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |
| 01/03/2003 | CA2450758A1 Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases |
| 01/03/2003 | CA2450748A1 Pharmaceutical compositions containing polymer and drug assemblies |
| 01/03/2003 | CA2450583A1 Antihistamines for the treatment of nasal congestion and nasal obstruction |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450550A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 01/03/2003 | CA2450491A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450446A1 Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| 01/03/2003 | CA2450002A1 Benzenesulfonyl(thio)ureas for the treatment of septic shock and sirs |
| 01/03/2003 | CA2450001A1 Stable pharmaceutical compositions containing pravastatin |
| 01/03/2003 | CA2449998A1 Stable controlled release pharmaceutical compositions containing pravastatin |
| 01/03/2003 | CA2449844A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/03/2003 | CA2449441A1 3-fluoro-pyrrolidines as antidiabetic agents |
| 01/03/2003 | CA2449439A1 Particles for inhalation having rapid release properties |
| 01/02/2003 | WO2002002529A1 Bicyclic lactams and sulfonamides with 5-ht1a-affinity and use thereof for preventing and treating cerebral ischaemia |
| 01/02/2003 | US20030004351 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 01/02/2003 | US20030004350 Pyrrolo(2,3-b)pyridine derivatives; anticancer and antiproliferative agents |
| 01/02/2003 | US20030004340 Skin disorders; gastrointestinal disorders |
| 01/02/2003 | US20030004327 Cerebellum and embryo specific protein |
| 01/02/2003 | US20030004317 Nucleic acids encoding anti-human alphanubeta3 and alphanubeta5 antibodies |
| 01/02/2003 | US20030004315 Collagen |
| 01/02/2003 | US20030004212 Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists |
| 01/02/2003 | US20030004211 Carbohydrate modifying agent and drinks containing the modifying agent |
| 01/02/2003 | US20030004210 Coupling to cell binding agent; killing cells |
| 01/02/2003 | US20030004206 Hypotensive agents; cardiovascular disorders |
| 01/02/2003 | US20030004200 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-YL] benzenesulfonamide |
| 01/02/2003 | US20030004187 Method for preventing dyskinesias |
| 01/02/2003 | US20030004186 Anticoagulants; cardiovascular disorders; central nervous system disorders |
| 01/02/2003 | US20030004180 Central nervous system disorders; psychological disorders |
| 01/02/2003 | US20030004176 Mixture of analgesic and addition reducting compound of a gamma-aminobutyric acid |
| 01/02/2003 | US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders |
| 01/02/2003 | US20030004173 Pharmaceutically active compounds |
| 01/02/2003 | US20030004172 Cardiovascular disorders, osteoporosis, multiple sclerosis, antiarthritic agents |
| 01/02/2003 | US20030004169 Modulators of dopamine neurotransmission |
| 01/02/2003 | US20030004168 Mixture of hypotensive agent and calcium channel blockers; cardiovascular disorders |
| 01/02/2003 | US20030004166 Novel triazine compounds useful as sorbitol dehydrogenase inhibitors |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004163 Antiinflammatory agents; headaches; antiarthritic agents |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004157 Neurokinin antagosnist receptor |
| 01/02/2003 | US20030004156 Anticholesterol agents; cardiovascular disorders; antidiabetic agents; antiproliferative agents |
| 01/02/2003 | US20030004154 New crystal forms of oxcarbazepine and processes for their preparation |
| 01/02/2003 | US20030004153 Novel heteroaryl-diazabicycloalkanes |
| 01/02/2003 | US20030004151 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/02/2003 | US20030004147 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 01/02/2003 | US20030004146 Compositions for preventing hormone induced adverse effects |
| 01/02/2003 | US20030004139 Antidiabetic agents |
| 01/02/2003 | US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents |
| 01/02/2003 | US20030004127 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004126 Formulations of adenosine A1 agonists |
| 01/02/2003 | US20030004118 Antibiotic/benzoyl peroxide dispenser |
| 01/02/2003 | US20030004117 Methods for inhibiting angiogenesis |
| 01/02/2003 | US20030004107 Method of preventing cell death using segments of neural thread proteins |
| 01/02/2003 | US20030004099 The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030004092 Methods and agents for inducing apoptosis and methods for their identification |
| 01/02/2003 | US20030003576 Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
| 01/02/2003 | US20030003574 Multipotent stem cells from peripheral tissues and uses thereof |
| 01/02/2003 | US20030003556 Human collagenase inhibitor, recombinant vector system for using same and recombinant DNA method for the manufacture of same |
| 01/02/2003 | US20030003555 Nucleotide sequences coding proteins for use in the diagnosis and treatment of hematopoietic or immune disorders |
| 01/02/2003 | US20030003545 Nucleotide sequences coding polypeptide for use in the treatment of immunological defects |
| 01/02/2003 | US20030003541 Nucleotide sequences coding peptide for use in the treatment of skin, brain and eye disorders |
| 01/02/2003 | US20030003516 Therapeutic and diagnostic uses of antibody specificity profiles |
| 01/02/2003 | US20030003462 Novel human interleukin-like proteins and polynucleotides encoding them |
| 01/02/2003 | US20030003445 Method of preventing cell death using antibodies to neural thread proteins |